Millennium Management’s Anika Therapeutics ANIK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-26,154
Closed -$251K 5675
2025
Q4
$251K Sell
26,154
-60,720
-70% -$582K ﹤0.01% 5356
2025
Q3
$817K Sell
86,874
-46,799
-35% -$447K ﹤0.01% 4770
2025
Q2
$1.41M Buy
133,673
+56,125
+72% +$708K ﹤0.01% 4158
2025
Q1
$1.17M Buy
77,548
+52,045
+204% +$866K ﹤0.01% 4241
2024
Q4
$420K Sell
25,503
-14,006
-35% -$276K ﹤0.01% 4868
2024
Q3
$976K Buy
39,509
+8,797
+29% +$228K ﹤0.01% 4300
2024
Q2
$778K Sell
30,712
-85,381
-74% -$2.21M ﹤0.01% 4287
2024
Q1
$2.95M Sell
116,093
-211,549
-65% -$5.12M ﹤0.01% 3386
2023
Q4
$7.42M Sell
327,642
-246,897
-43% -$5.11M ﹤0.01% 2453
2023
Q3
$10.7M Buy
574,539
+443,763
+339% +$9.2M 0.01% 1989
2023
Q2
$3.4M Buy
130,776
+122,659
+1,511% +$3.28M ﹤0.01% 3020
2023
Q1
$233K Sell
8,117
-121,844
-94% -$3.63M ﹤0.01% 5082
2022
Q4
$3.85M Buy
129,961
+120,092
+1,217% +$3.42M ﹤0.01% 3025
2022
Q3
$235K Sell
9,869
-26,996
-73% -$621K ﹤0.01% 5545
2022
Q2
$823K Buy
+36,865
New +$822K ﹤0.01% 4551
2022
Q1
Sell
-30,325
Closed -$1.09M 6864
2021
Q4
$1.09M Sell
30,325
-919
-3% -$36.8K ﹤0.01% 4334
2021
Q3
$1.33M Sell
31,244
-13,208
-30% -$544K ﹤0.01% 4368
2021
Q2
$1.92M Sell
44,452
-78,874
-64% -$3.36M ﹤0.01% 4005
2021
Q1
$5.03M Buy
123,326
+99,036
+408% +$3.76M ﹤0.01% 2562
2020
Q4
$1.1M Buy
+24,290
New +$922K ﹤0.01% 3679
2020
Q2
Sell
-59,236
Closed -$1.71M 4141
2020
Q1
$1.71M Sell
59,236
-36,778
-38% -$1.49M ﹤0.01% 2120
2019
Q4
$4.98M Sell
96,014
-95,947
-50% -$5.57M 0.01% 1946
2019
Q3
$10.5M Sell
191,961
-96,864
-34% -$4.97M 0.02% 1248
2019
Q2
$11.7M Buy
288,825
+62,268
+27% +$2.27M 0.02% 1133
2019
Q1
$6.85M Buy
226,557
+36,009
+19% +$1.23M 0.01% 1542
2018
Q4
$6.4M Buy
190,548
+99,387
+109% +$3.59M 0.01% 1417
2018
Q3
$3.85M Buy
91,161
+27,326
+43% +$1.08M ﹤0.01% 1995
2018
Q2
$2.04M Buy
63,835
+20,420
+47% +$841K ﹤0.01% 2382
2018
Q1
$2.16M Buy
43,415
+39,554
+1,024% +$2.23M ﹤0.01% 2263
2017
Q4
$208K Sell
3,861
-3,982
-51% -$220K ﹤0.01% 3515
2017
Q3
$455K Buy
+7,843
New +$410K ﹤0.01% 2885
2017
Q2
Sell
-86,892
Closed -$3.77M 3428
2017
Q1
$3.77M Buy
86,892
+50,613
+140% +$2.42M 0.01% 1618
2016
Q4
$1.78M Sell
36,279
-149,509
-80% -$6.91M ﹤0.01% 1937
2016
Q3
$8.89M Buy
185,788
+148,166
+394% +$7.32M 0.01% 997
2016
Q2
$2.02M Sell
37,622
-22,731
-38% -$1.07M ﹤0.01% 1779
2016
Q1
$2.7M Sell
60,353
-103,956
-63% -$4.22M 0.01% 1624
2015
Q4
$6.27M Sell
164,309
-71,780
-30% -$2.75M 0.01% 1212
2015
Q3
$7.51M Buy
236,089
+111,865
+90% +$3.9M 0.01% 1103
2015
Q2
$4.1M Buy
124,224
+74,224
+148% +$2.65M 0.01% 1513
2015
Q1
$2.06M Sell
50,000
-120,096
-71% -$4.86M ﹤0.01% 1924
2014
Q4
$6.93M Sell
170,096
-205,733
-55% -$8.04M 0.01% 1191
2014
Q3
$13.8M Buy
375,829
+253,405
+207% +$11M 0.03% 694
2014
Q2
$5.67M Buy
122,424
+25,272
+26% +$1.12M 0.02% 1135
2014
Q1
$3.99M Buy
97,152
+72,452
+293% +$2.69M 0.01% 1334
2013
Q4
$943K Buy
24,700
+13,335
+117% +$411K ﹤0.01% 2331
2013
Q3
$272K Sell
11,365
-1,615
-12% -$36.3K ﹤0.01% 2922
2013
Q2
$221K Buy
+12,980
New +$187K ﹤0.01% 2708

Other funds holding ANIK

Millennium Management's ANIK Position: Q1 2026 in Review

Millennium Management sold out of Anika Therapeutics (ANIK) in Q1 2026, closing a stake of 26,154 shares — an estimated $251K sold.

Millennium Management first reported a position in ANIK in Q2 2013 and held it in 47 quarters. The position peaked at $13.8M in Q3 2014. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Millennium Management reported no remaining Anika Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Millennium Management sold 26,154 Anika Therapeutics shares in Q1 2026, an estimated $251K.
  • Millennium Management first reported a position in Anika Therapeutics in Q2 2013 and held it in 47 quarters.
  • Millennium Management's Anika Therapeutics position peaked at $13.8M in Q3 2014.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.